Anti-infective Agents : Tetracyclines
ITYGA1 “Tygacil Lypophilized powder for injection ” 50 mg/vial
ITIGE1 “Tigelin Lyophilized powder for injection” 50 mg/vial
適應症：對Tigecycline具有感受性之細菌所引起之複雜性皮膚及皮膚結構感染、複雜性腹腔內感染症及社區感染性肺炎。
Usual dose:
Community acquired pneumonia:
Initial dose, 100 mg IV followed by 50 mg IV every 12 hours; duration is for 7 to 14 days depending on the severity and site of infection.
Infection of skin AND/OR subcutaneous tissue, Complicated:
Initial dose, 100 mg IV followed by 50 mg IV every 12 hours; duration is for 5 to 14 days depending on the severity and site of infection.
Infectious disease of abdomen, Complicated:
Initial dose, 100 mg IV followed by 50 mg IV every 12 hours; duration is for 5 to 14 days depending on the severity and site of infection.
Dose adjustment:
Hepatic impairment: severe (Child-Pugh C), initial dose, 100 mg IV followed by 25 mg IV every 12 hours.
Contraindication:
Known hypersensitivity to tigecycline.
Precaution:
Acute pancreatitis, including fatal cases, has been reported. Permanent tooth discoloration may occur when used during tooth development (last half of pregnancy, infancy, and childhood to 8 years of age); avoid use unless there is no effective alternative.Clostridium difficile-associated diarrhea ranging from mild diarrhea to fatal colitis has been reported to occur even more than 2 months after last dose; discontinuation may be necessary.
Adverse effect:
Common: abdominal pain, diarrhea, nausea, vomiting, headache.
Serious: septic shock, clostridium difficile diarrhea, pancreatitis, acute pancreatitis, ALT/SGPT level raised, AST/SGOT level raised, disease of liver, hyperbilirubinemia, liver failure, anaphylaxis, pseudotumor cerebri, all-cause, sepsis.
健保使用規範：
1.限下列條件之一使用：
(1)經細菌培養證實有意義之致病菌且對其他抗微生物製劑均具抗藥性或對其他具有感受性抗微生物製劑過敏，而對tigecycline具有感受性(sensitivity)之複雜性皮膚及皮膚結構感染或複雜性腹腔內感染症使用。
(2)其他經感染症專科醫師會診，認定需使用之下列感染症：複雜性皮膚及皮膚結構感染、複雜性腹腔內感染、社區感染性肺炎。(100/7/1)
2.申報費用時需檢附會診紀錄或相關之病歷資料。